GE HealthCare Technologies Inc. $GEHC Shares Sold by Rathbones Group PLC

04 Aug 2026, 09:58 by Kim Johansen · The Markets Daily

Rathbones Group PLC lessened its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report) by 2.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 357,748 shares of the company’s stock after selling 7,597 shares during the period. Rathbones Group PLC owned about 0.08% of GE HealthCare Technologies worth $25,465,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Laurel Wealth Advisors LLC bought a new stake in GE HealthCare Technologies during the fourth quarter valued at $26,000. Optima Capital LLC bought a new position in shares of GE HealthCare Technologies in the 4th quarter worth about $27,000. Godfrey Financial Associates Inc. bought a new position in shares of GE HealthCare Technologies in the 4th quarter worth about $27,000. Montag A & Associates Inc. boosted its holdings in shares of GE HealthCare Technologies by 105.4% in the 4th quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock valued at $28,000 after buying an additional 175 shares during the period. Finally, Transamerica Financial Advisors LLC boosted its holdings in shares of GE HealthCare Technologies by 331.6% in the 4th quarter. Transamerica Financial Advisors LLC now owns 341 shares of the company’s stock valued at $28,000 after buying an additional 262 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

GE HealthCare Technologies Stock Up 2.5%

GE HealthCare Technologies stock opened at $69.73 on Tuesday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.97 and a current ratio of 1.26. GE HealthCare Technologies Inc. has a one year low of $58.75 and a one year high of $89.77. The company has a 50-day simple moving average of $64.13 and a 200-day simple moving average of $70.33. The firm has a market capitalization of $31.50 billion, a P/E ratio of 15.99, a P/E/G ratio of 1.97 and a beta of 0.72.

GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.04 by $0.09. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.26 billion. GE HealthCare Technologies had a net margin of 9.33% and a return on equity of 20.12%. GE HealthCare Technologies’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm posted $1.06 EPS. As a group, equities analysts expect that GE HealthCare Technologies Inc. will post 4.91 earnings per share for the current year.

GE HealthCare Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Friday, July 24th will be paid a $0.035 dividend. The ex-dividend date is Friday, July 24th. This represents a $0.14 annualized dividend and a dividend yield of 0.2%. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 3.21%.

Insider Activity

In other GE HealthCare Technologies news, Director Watkin Phoebe L. Yang purchased 1,000 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were bought at an average price of $63.01 per share, with a total value of $63,010.00. Following the completion of the acquisition, the director owned 13,702 shares in the company, valued at approximately $863,363.02. This represents a 7.87% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Rodney F. Hochman acquired 1,618 shares of GE HealthCare Technologies stock in a transaction dated Tuesday, May 12th. The shares were acquired at an average price of $62.03 per share, with a total value of $100,364.54. Following the completion of the transaction, the director owned 1,618 shares of the company’s stock, valued at approximately $100,364.54. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 12,618 shares of company stock valued at $805,175. Insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

GEHC has been the topic of several research reports. JPMorgan Chase & Co. dropped their price objective on shares of GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating on the stock in a research note on Thursday, April 30th. Hovde Group assumed coverage on GE HealthCare Technologies in a research note on Friday, July 17th. They issued a “market perform” rating and a $14.00 target price for the company. The Goldman Sachs Group reaffirmed a “neutral” rating on shares of GE HealthCare Technologies in a report on Monday, June 8th. Rothschild & Co Redburn dropped their price target on GE HealthCare Technologies from $110.00 to $98.00 in a research report on Thursday, April 30th. Finally, Citigroup raised their price target on GE HealthCare Technologies from $69.00 to $75.00 and gave the stock a “neutral” rating in a report on Thursday. Ten investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, GE HealthCare Technologies currently has a consensus rating of “Hold” and an average target price of $77.73.

Check Out Our Latest Stock Report on GEHC

GE HealthCare Technologies Company Profile

(Free Report)

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.